Atossa Genetics Inc. (ATOS) financial statements (2020 and earlier)

Company profile

Business Address 107 SPRING STREET
SEATTLE, WA 98104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13107349
Cash and cash equivalents13107349
Restricted cash and investments0000  
Receivables  0  0
Inventory, net of allowances, customer advances and progress billings     0
Inventory     0
Prepaid expense110000
Other current assets000 0 
Other undisclosed current assets11  0 
Total current assets:14128349
Noncurrent Assets
Operating lease, right-of-use asset0
Property, plant and equipment000000
Intangible assets, net (including goodwill)  0122
Intangible assets, net (excluding goodwill)  0122
Deferred costs     0
Other noncurrent assets000000
Other undisclosed noncurrent assets00    
Total noncurrent assets:000123
TOTAL ASSETS:141284612
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities111122
Accounts payable000011
Accrued liabilities000000
Employee-related liabilities111111
Debt0     
Deferred compensation liability 1    
Other liabilities000000
Other undisclosed current liabilities     0
Total current liabilities:131132
Noncurrent Liabilities
Long-term debt and lease obligation, including:0    0
Operating lease, liability0
Other undisclosed long-term debt and lease obligation     0
Liabilities, other than long-term debt     0
Deferred revenue and credits   0
Total noncurrent liabilities:0    0
Total liabilities:131132
Stockholders' equity
Stockholders' equity attributable to parent1397349
Preferred stock00    
Common stock210000
Additional paid in capital1068572605545
Accumulated deficit(94)(77)(65)(57)(51)(35)
Total stockholders' equity:1397349
TOTAL LIABILITIES AND EQUITY:141284612

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues
(Revenue, Net)
    01
Cost of revenue
(Cost of Goods and Services Sold)
    (0)(0)
Gross profit:    (0)0
Operating expenses(17)(11)(8)(8)(13)(15)
Operating loss:(17)(11)(8)(8)(13)(15)
Nonoperating income000200
Investment income, nonoperating  (0)(0) 0
Other nonoperating income00    
Interest and debt expense  (0)(0)(0)(0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes  (0) 0 
Loss from continuing operations before equity method investments, income taxes:(17)(11)(8)(6)(13)(15)
Other undisclosed income from continuing operations before income taxes   0  
Loss before gain (loss) on sale of properties:(17)(11)(8)(6)(13)(15)
Other undisclosed net loss    (3) 
Net loss attributable to parent:(17)(11)(8)(6)(16)(15)
Preferred stock dividends and other adjustments  (3)   
Other undisclosed net loss available to common stockholders, basic (11)    
Net loss available to common stockholders, diluted:(17)(23)(11)(6)(16)(15)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(17)(11)(8)(6)(16)(15)
Comprehensive loss, net of tax, attributable to parent:(17)(11)(8)(6)(16)(15)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: